Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

M. Hardy, T. Lecompte, J. Douxfils, S. Lessire, J. M. Dogne, B. Chatelain, S. Testa, I. Gouin-Thibault, Y. Gruel, R. L. Medcalf, H. ten Cate, G. Lippi, F. Mullier*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number17
Number of pages16
JournalThrombosis Journal
Volume18
Issue number1
DOIs
Publication statusPublished - 7 Sep 2020

Keywords

  • Thrombosis
  • D-dimers
  • Anticoagulation
  • COVID-19
  • Coagulopathy
  • Hemostasis
  • Fibrinolysis
  • Heparin
  • Thrombin generation
  • Viscoelastic tests
  • PARTIAL THROMBOPLASTIN TIME
  • PLASMINOGEN-ACTIVATOR INHIBITOR-1
  • HEPARIN-INDUCED THROMBOCYTOPENIA
  • PNEUMATIC TUBE SYSTEM
  • MONITORING UNFRACTIONATED HEPARIN
  • LOW FIBRINOGEN LEVELS
  • D-DIMER
  • VENOUS THROMBOEMBOLISM
  • SOLUBLE FIBRIN
  • CLINICAL CHARACTERISTICS

Cite this

Hardy, M., Lecompte, T., Douxfils, J., Lessire, S., Dogne, J. M., Chatelain, B., Testa, S., Gouin-Thibault, I., Gruel, Y., Medcalf, R. L., ten Cate, H., Lippi, G., & Mullier, F. (2020). Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis Journal, 18(1), [17]. https://doi.org/10.1186/s12959-020-00230-1